3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Hodgkin Disease
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioblastoma
2
Anemia, Refractory, with Excess of Blasts
2
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Extranodal NK-T-Cell
1
Hemoglobinuria, Paroxysmal
1
Gliosarcoma
1
Brain Neoplasms
1
Anemia, Aplastic
1
Interventions
Temozolomide
85
Radiotherapy
51
Bevacizumab
31
Irinotecan
19
Radiation
16
Carmustine
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
O(6)-benzylguanine
11
Chemotherapy, Adjuvant
11
Carboplatin
9
sargramostim
8
Thalidomide
8
Imatinib Mesylate
8
Filgrastim
8
Surgical Procedures, Operative
6
Gene Expression Profiling
6
Drug Therapy
6
pembrolizumab
5
aldesleukin
5
Topotecan
5
Radiotherapy, Intensity-Modulated
5
Hydroxyurea
5
Gefitinib
5
Etoposide
5
Sorafenib
4
Immunohistochemistry
4
Dasatinib
4
Celecoxib
4
Biopsy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gliosarcoma
×
Basiliximab
×
Clear all
NCT00626483
2021-03-09
REGULATe
Duke University
Phase 1
Completed
34 enrolled